Atossa Therapeutics (NASDAQ: ATOS) wins OK for potential reverse stock split
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Atossa Therapeutics, Inc. reported results of its 2026 Annual Meeting of Stockholders. As of the March 19, 2026 record date, 8,611,361 shares of common stock were entitled to vote. Stockholders elected three Class II directors and ratified Ernst & Young LLP as independent registered public accounting firm.
Stockholders also approved an amendment to the Amended and Restated Certificate of Incorporation authorizing a reverse stock split at a ratio from 2:1 to 20:1, if the board determines it is necessary or appropriate. In addition, stockholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Shares entitled to vote: 8,611,361 shares
Reverse split range: 2:1 to 20:1
Reverse split votes for: 2,336,815 votes
+3 more
6 metrics
Shares entitled to vote
8,611,361 shares
Common stock as of March 19, 2026 record date
Reverse split range
2:1 to 20:1
Authorized reverse stock split ratio range for common stock
Reverse split votes for
2,336,815 votes
Votes for amendment authorizing reverse stock split
Reverse split votes against
1,866,873 votes
Votes against amendment authorizing reverse stock split
Auditor ratification votes for
3,714,889 votes
Ratification of Ernst & Young LLP for fiscal year 2026
Say-on-pay votes for
1,530,390 votes
Advisory approval of named executive officer compensation
Key Terms
Annual Meeting of Stockholders, record date, reverse stock split, independent registered public accounting firm, +1 more
5 terms
Annual Meeting of Stockholders regulatory
"held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”)."
record date financial
"As of the close of business on March 19, 2026, the record date for the Annual Meeting"
The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.
reverse stock split financial
"to effect a reverse stock split at a ratio from 2:1 to 20:1, inclusive"
A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.
independent registered public accounting firm regulatory
"the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
non-binding, advisory basis regulatory
"approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers"
FAQ
What did Atossa Therapeutics (ATOS) report from its 2026 Annual Meeting?
Atossa Therapeutics reported that stockholders elected three Class II directors, ratified Ernst & Young LLP as auditor for 2026, approved a potential reverse stock split authority, and supported executive compensation in a non-binding advisory vote at the 2026 Annual Meeting.
What were the results of Atossa Therapeutics (ATOS) advisory vote on executive pay?
In the advisory say-on-pay proposal, Atossa Therapeutics stockholders cast 1,530,390 votes for, 444,616 against, and 39,793 abstaining, with 2,222,160 broker non-votes, thereby approving on a non-binding basis the compensation of the company’s named executive officers.
Were Atossa Therapeutics (ATOS) director nominees elected at the 2026 meeting?
Yes. Stockholders elected Class II directors Stephen J. Galli, Richard I. Steinhart, and Tessa Cigler, with each nominee receiving more votes for than withheld, alongside 2,222,160 broker non-votes recorded for the director election proposals at the 2026 Annual Meeting.